Richard E. Pratley, MD
PHILADELPHIA — Treatment with the SGLT2 inhibitor dapagliflozin reduced risk for CV death and worsening HF across a broad spectrum of age, independent of symptomatic impairment at baseline, according to two new post-hoc analyses of the DAPA-HF trial presented at the American Heart Association Scientific Sessions.
The analyses also showed dapagliflozin (Farxiga, AstraZeneca) improved symptom burden, physical function and quality of life in patients with HF with reduced ejection fraction.
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.
Discoveries from ADA: Updates in Pharmacology
Search Healio's robust listing of national and international medical meetings.
Tell us what you think about Healio.com »
Get the latest news and education delivered to your inbox
©2019 Healio All Rights Reserved.